ArticleBMC neurology2026
Untargeted red blood cell metabolomics reveals distinct metabolic signatures in malignant cerebral edema following acute ischemic stroke.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMalignant cerebral edema (MCE) is a major cause of mortality and disability in acute ischemic stroke, yet effective treatments remain limited. Early identification of patients at high risk for MCE is therefore an important unmet clinical need.
methodsPatients with large vessel occlusion acute ischemic stroke (LVO-AIS) were prospectively enrolled. All patients had radiologically confirmed LVO and underwent follow-up neuroimaging for cerebral edema assessment. MCE was defined as cerebral edema grade 3 (CED-3) on the Thrombolysis in Stroke–Monitoring Study edema scale, while non-MCE was defined as CED-1–2. In a pilot screening phase, plasma, red blood cell (RBC), and urine samples were collected on days 1, 3, and 7 after stroke onset from a subset of patients to identify the most informative biofluid and sampling time point. Based on these results, untargeted metabolomic profiling using ultrahigh-performance liquid chromatography–tandem mass spectrometry was performed in RBC samples collected within 24 h of stroke onset from an expanded cohort.
resultsPilot screening (n = 3 per group) indicated that day 1 RBC samples showed the most pronounced metabolic differences between patients who later developed MCE and those who did not. Accordingly, day 1 RBCs from 61 patients (19 MCE, 42 non-MCE) were analyzed. Untargeted metabolomic analysis identified 521 differentially abundant metabolites, including 177 upregulated and 344 downregulated features in the MCE group. Key altered metabolites included palmitoylethanolamide, S-adenosylmethionine, and spermidine, with enrichment in pathways related to cofactor biosynthesis, neuroactive ligand–receptor interactions, and amino acid metabolism.
conclusionRed blood cell metabolomic profiles within 24 h of stroke onset differ between patients who subsequently develop malignant cerebral edema and those who do not. These findings provide exploratory insights into early metabolic alterations associated with MCE and warrant further validation in larger, targeted studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.